Technical Analysis for CNSP - CNS Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.42 | -10.13% | -0.16 |
CNSP closed down 10.13 percent on Monday, July 1, 2024, on 39 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Possible NR7 | about 6 hours ago |
| Down 10% | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| Up 1% | about 10 hours ago |
| Down 5% | about 10 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/12/2024
CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. Its lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. The company was founded in 2017 and is based in Houston, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Oncology Blastoma Glioblastoma Stage Pharmaceutical Brain Tumor Evofosfamide Central Nervous System Tumors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Oncology Blastoma Glioblastoma Stage Pharmaceutical Brain Tumor Evofosfamide Central Nervous System Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 137.5 |
| 52 Week Low | 1.4 |
| Average Volume | 515,667 |
| 200-Day Moving Average | 41.33 |
| 50-Day Moving Average | 7.68 |
| 20-Day Moving Average | 3.32 |
| 10-Day Moving Average | 2.10 |
| Average True Range | 1.14 |
| RSI (14) | 21.88 |
| ADX | 36.3 |
| +DI | 37.45 |
| -DI | 24.60 |
| Chandelier Exit (Long, 3 ATRs) | 8.99 |
| Chandelier Exit (Short, 3 ATRs) | 4.81 |
| Upper Bollinger Bands | 6.45 |
| Lower Bollinger Band | 0.19 |
| Percent B (%b) | 0.2 |
| BandWidth | 188.67 |
| MACD Line | -1.96 |
| MACD Signal Line | -2.02 |
| MACD Histogram | 0.0675 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.72 | ||||
| Resistance 3 (R3) | 1.75 | 1.67 | 1.67 | ||
| Resistance 2 (R2) | 1.67 | 1.60 | 1.66 | 1.65 | |
| Resistance 1 (R1) | 1.55 | 1.55 | 1.51 | 1.52 | 1.64 |
| Pivot Point | 1.47 | 1.47 | 1.46 | 1.46 | 1.47 |
| Support 1 (S1) | 1.35 | 1.40 | 1.31 | 1.32 | 1.20 |
| Support 2 (S2) | 1.27 | 1.35 | 1.26 | 1.19 | |
| Support 3 (S3) | 1.15 | 1.27 | 1.17 | ||
| Support 4 (S4) | 1.12 |
